TY - JOUR T1 - Aerosol particle concentrations with different oxygen devices and interfaces for spontaneous breathing patients with tracheostomy: a randomized cross-over trial JF - ERJ Open Research JO - erjor DO - 10.1183/23120541.00486-2021 SP - 00486-2021 AU - Jie Li AU - Carla Schoenrock AU - James B. Fink Y1 - 2021/01/01 UR - http://openres.ersjournals.com/content/early/2021/08/26/23120541.00486-2021.abstract N2 - The transmission route of the SARS-CoV-2 virus remains controversial [1, 2], and concerns persist of potentially increased virus transmission and aerosol dispersion when utilizing high-flow oxygen and aerosol devices among COVID-19 patients [2–5]. Spontaneous breathing patients with tracheostomy represent a more direct conduit for dispersing aerosol particles with risk of virus transmission [6]. Tracheostomy procedure is considered a high-risk aerosol generating procedure and high-level personal protection equipment (PPE) is recommended when the tracheostomy is being performed for COVID-19 patients [7]. However aerosol dispersion transmission risk of bioaerosols via tracheostomy during spontaneous breathing has not been evaluated and the impact of different humidification devices and interfaces are unknown.FootnotesThis manuscript has recently been accepted for publication in the ERJ Open Research. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJOR online. Please open or download the PDF to view this article.Conflict of interest: Dr. Li reports grants from Fisher & paykel, during the conduct of the study; grants and personal fees from Fisher & Paykel Healthchare Ltd, grants and personal fees from Aerogen Ltd, personal fees from AARC, personal fees from Respiratory care journal, grants from Rice Foundation, outside the submitted work; .Conflict of interest: Dr. Schoenrock has nothing to disclose.Conflict of interest: Dr. Fink is Chief Science Officer for Aerogen Pharma Corp. ER -